29 Oct 2018

UCB First Nine Months Interim Report 2018: UCB tracking well towards full year financial outlook

Read More
23 Oct 2018

Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients

Read More
22 Oct 2018

UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

Read More
18 Oct 2018

UCB Presents New Long-Term Data Showing Substantial Impact for CIMZIA® (Certolizumab Pegol) in Axial Spondyloarthritis and Rheumatoid Arthritis and Late-Breaking Bimekizumab Data in Psoriatic Arthritis 

Read More
18 Oct 2018

UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development Phase

Read More
18 Oct 2018

The impact of fragility fractures due to osteoporosis is being ignored

Read More
12 Oct 2018

Transparency notification BlackRock, Inc.

Read More
5 Oct 2018

Transparency notifications BlackRock, Inc.

Read More
2 Oct 2018

Transparency notifications BlackRock, Inc.

Read More
24 Sep 2018

UCB Highlights Data to Be Presented At American Society for Bone and Mineral Research 2018 Annual Meeting

Read More
Subscribe to